<DOC>
	<DOCNO>NCT00001954</DOCNO>
	<brief_summary>This study test effectiveness etanercept ( Enbrel ) treat Sjogren 's syndrome-an autoimmune disease affect secrete gland . ( In autoimmune disease , immune system attack body 's tissue . ) Reduced lacrimal ( tear ) gland function cause dry eye scratchy sensation , , severe case , vision may impair . Reduced salivary gland function cause dry mouth , result greatly increase tooth decay . Dry mouth also make chew swallow difficult , may lead nutrition deficiency . Sjogren 's syndrome also cause dryness skin mucous membrane nose , throat , airway , vagina . Patients Sjogren 's syndrome oral eye examination NIDCR 's protocol 84-D-0056 may participate study . Participants randomly assign receive either etanercept placebo ( inactive look-alike substance ) injection skin twice week 3 month . Patients see evaluation treatment begin ( baseline ) 1 , 3 , 4 month . The baseline 3-month visit include physical examination , eye examination , saliva collection salivary gland , blood test , evaluation change symptoms treatment side effect . The 1- 4-month visit include saliva collection , blood test , review symptom treatment side effect . In addition , blood drawn every 2 week safety monitoring . Patients also survey weekly ( telephone clinic visit ) symptoms treatment side effect . The Food Drug Administration approve Enbrel treat certain form arthritis , , like Sjogren 's syndrome , autoimmune disorder connective tissue . Laboratory study also indicate etanercept may effective treatment Sjogren 's syndrome .</brief_summary>
	<brief_title>Etanercept Therapy Sjogren 's Syndrome</brief_title>
	<detailed_description>Sjogren 's syndrome ( SS ) autoimmune disease chiefly affect exocrine gland . Manifestations SS include salivary lacrimal gland dysfunction . There generally accept treatment underlie autoimmune reactivity exocrine gland dysfunction SS . We propose test effect etanercept therapy . In randomized , double-masked , outpatient protocol , patient receive etanercept 2 times/week 3 month . Therapy give subcutaneous injection . Efficacy treatment assess monitoring salivary lacrimal function , serological marker autoimmune activity , subjective report local systemic symptom . The present trial serve screen protocol identify etanercept analyze large clinical trial efficacy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>INCLUSION CRITERIA Documented primary secondary SS . Absence confound health problem . No contraindication etanercept therapy . SS patient sarcoidosis , HIV infection , lymphoma . Patients must one follow abnormal autoimmune serology associate SS ( i.e . positive ANA , RF , antiSSA , antiSSB ) . Patients may use pilocarpine provide hold dose visit day saliva collect . Patients take DMARD 's , hydroxychloroquine , must stable dose . Participants may take NSAIDs acetaminophen . EXCLUSION CRITERIA Patients must physical mental condition may make unable comply . Subjects may continue longterm medication exception tricyclic antidepressant anticholinergic , may affect salivary gland function . Patients take experimental drug duration protocol . Children exclude due additional risk may occur etanercept .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>Clinical Trial</keyword>
	<keyword>Autoimmune</keyword>
	<keyword>Disease Activity</keyword>
	<keyword>Cytokine</keyword>
	<keyword>Saliva</keyword>
	<keyword>Xerostomia</keyword>
	<keyword>Salivary Glands</keyword>
	<keyword>Sjogren 's Syndrome</keyword>
</DOC>